Search the Newsreel

Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit

Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an …

Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants

Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collateral. These …

Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its drug candidates. The agreement also adjusts …

Robinhood Stock And 2 More Ways To Invest In The Speculation Boom

Robinhood Markets Inc (HOOD) adds a 14.2% weekly gain to a three-month surge

The capital-markets fintech is extending a strong run, though lighter volume and negative Relative Strength keep the confirmation mixed.

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn Continues - Share Repurchase Impact

Einhell setzt auf Akku-Ökosystem und internationale Expansion – Power X-Change wird zum Wachstumsmotor

Robinhood Markets Inc (HOOD) weekly rally stretches despite thin confirmation

A 52-week weekly view shows the retail broker’s rebound spanning more than the latest print, while technical and volume signals remain uneven.

Previsão SMTO3 — Preço Alvo para 2027

Previsão VAMO3 — Preço Alvo para 2027

Robinhood Markets Inc (HOOD) weekly advance lifts four-week gain to 46.9%

The online brokerage finished the latest week at $108.15, with strong medium-term returns offset by inactive trend status and negative Relative Strength.

Shinhan’s 65% Fair Value premium meets a negative pressure read after regional-bank pullback

Shinhan Financial’s weekly trend remains active, but the latest down week came with only normal participation and a still-negative Market Dynamics read.

Robinhood’s 16.1% week clears the Trend Line, with Relative Strength still below zero

HOOD has staged a forceful four-week recovery, but the Sharemaestro read remains mixed: price is back above trend, activity pressure is positive, and volume improved, while the Trend backdrop and Relative Strength have not fully confirmed.

Robinhood Markets Inc (HOOD) extends four-week run to 46.9%

The capital-markets fintech’s rally remains forceful, but trend and Relative Strength readings keep the setup from looking one-way.

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

Minho (M) Berhad's (KLSE:MINHO) Solid Earnings May Rest On Weak Foundations

Vamos (VAMO3) tem lucro líquido de R$ 87 milhões no 1T26, queda anual de -20%

Inhibikase Therapeutics (IKT) Holds Near Support Amid Modest Gains - Late Stage Breakouts

Transcrição do call de resultados: São Martinho surpreende no 4T 2025/2026 - Investing.com Brasil

São Martinho (SMTO3) | Revisão dos resultados do 4T26: alfa operacional, beta estrutural

Inhibikase Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines - Slow Growth Warning

Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT

Brainhole Technology Limited Announces Major Transaction: Further Disposal of Nebius Shares – Financial Impact and Strategic Investment Update – Minichart

Vamos (VAMO3) tem lucro líquido de R$ 86,6 milhões no 1º trimestre, queda de 20%

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Lucro líquido da Vamos (VAMO3) soma R$ 77 milhões no 4T25, queda de 52,6% ante 4T24

Vamos Locacao De Caminhoes Maquinas E Equipamentos SA (VAMO3)

A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress

Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty

Lucro de São Martinho (SMTO3) cresce com efeitos não recorrentes

São Martinho dispara lucro no 3T da safra 2025/26, apesar de queda no Ebitda

Einhell Germany AG Vz Aktie Kurs & Chart A40ESU

Ibovespa na semana: Vamos (VAMO3) dispara 9% com prévia de resultados; C&A (CEAB3) afunda

Vamos (VAMO3) acelera receita no 4º trimestre, mas venda de veículos fica abaixo do projetado; ações avançam acima de 5,4%

São Martinho (SMTO3) tem queda no lucro no 2º tri da safra 25/26 e reduz projeções de produção e investimentos

Vamos (VAMO3) no 3T25: receita cresce, mas lucro recua; o que fazer agora?